The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma Authors: Ayako Kamiunten, Daisuke Morishita, Takuro Kameda, Midori Sugiyama, Shunsuke Ebara, Yasunori Kogure, Akio Mizutani, Takaharu Hirayama, Tomohiro Kawamoto, Yotaro Ochi, Kotaro Shide, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Takamitsu Maru, Hideyuki Oki, Akinori Yoda, Yuki Tahira, Ryoma Ikeda, Kengo Matsumoto, Masayoshi Karasawa, Keiichi Akizuki, Masaaki Sekine, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Hideki Yamaguchi, Hiroo Hasegawa, Yoshitaka Imaizumi, Jun-ichirou Yasunaga, Masao Matsuoka, Makoto Yoshimitsu, Kenji Ishitsuka, Keisuke Kataoka, Seishi Ogawa, Kazuya Shimoda Published: 2026 ABSTRACT SummaryAdult T cell leukemia/lymphoma (ATL) is an aggressive T cell malignancy with poor prognosis. Recurrent genetic alterations in T cell receptor (TCR) signaling components, including PLCG1, PRKCB, and CARD11, highlight the biological relevance of this pathway in ATL. We focused on mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), a key regulator of TCR signaling that functions through complex formation with CARD11 and BCL10, and developed a potent and selective MALT1 protease inhibitor, CRD-1441551. CRD-1441551 exhibited variable antitumor effects across ATL models both in vitro and in vivo. Among three ATL cell lines and five patient-derived xenograft models, two demonstrated marked sensitivity, three showed modest responses, and three were unresponsive. Notably, therapeutic responses were more frequently observed in models with constitutive MALT1 activation accompanied by enhanced MALT1-NF-κB signaling. These findings suggest that CRD-1441551 preferentially targets a subset of ATL, in which tumor growth is dependent on the MALT1-driven NF-κB pathway. Introduction Adult T-cell leukemia/lymphoma (ATL) is an aggressive peripheral T cell malignancy that develops in approximately 5% of individuals after decades have elapsed since their infection with human T cell lymphotropic virus type-1 (HTLV-1).1,2,3,4,5 ATL is classified into four types: acute, lymphoma, chronic, and smoldering. The current standard chemotherapy for aggressive ATL (acute, lymphoma, or unfavorable chronic type) is dose-intensified multidrug chemotherapy; however, the prognosis remains poor despite treatment, with a median survival time of 13 months.6,7 The chemokine receptor 4 (CCR4) antibody mogamulizumab, the immunomodulatory drug lenalidomide, the histone deacetylase inhibitor tucidinostat, the EZH1/2 inhibitor valemetostat, and hematopoietic stem cell transplantation have all been employed to improve the prognosis.8,9,10,11,12 We previously reported comprehensive genomic alterations in ATL and found that driver gene alterations were strongly enriched in components of the T cell receptor (TCR)-NF-κB signaling pathway.13,14 The most frequent alterations involved PLCG1, PRKCB, and CARD11, which encode phospholipase Cγ1 (PLCγ1), a member of the protein kinase C (PKC) family of proteins (PKCβ), and a cytoplasmic scaffolding protein (CARD11), respectively. PLCγ1 is a key regulator of proximal TCR signaling, whereas PKCβ and CARD11 regulate distal TCR signaling. As these mutations are known or predicted gain-of-function mutations, they are likely to be responsible for the enhanced activation of TCR-NF-κB signaling in most cases of ATL, as previously reported by electrophoretic mobility shift assays in patient samples from ATL.15 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a multifunctional protein essential for activating the NF-κB signaling pathway.16 Upon antigen receptor triggering, MALT1 facilitates the formation of the CARD11-BCL10-MALT1 (CBM) complex and recruits the ubiquitin ligase TRAF6.17 This recruitment subsequently activates the IκB kinase (IKK) complex, which then leads to the degradation of IκB, a known NF-κB inhibitor, thereby initiating NF-κB activation. Furthermore, MALT1 contains a paracaspase domain that cleaves multiple substrates involved in immune signaling. These include negative regulators of the NF-κB pathway, such as A20, CYLD, and RelB, whose cleavage promotes NF-κB activation,18,19,20 as well as BCL10, whose cleavage modulates and limits CBM-dependent signaling. In addition, MALT1 targets RNA-binding proteins, including Regnase-1 and Roquin-1/2, thereby regulating mRNA stability and contributing to the amplification of inflammatory gene expression.21,22 Genetic alterations that affect the NF-κB and BCL6-BLIMP1 axis have been reported in the activated B-cell (ABC)-like subtype of diffuse large B cell lymphoma (DLBCL).23 Pharmacologic inhibition of MALT1 protease activity selectively suppressed the growth of ABC-type DLBCL cells.24,25,26,27 For example, inhibition of MALT1 protease activity by the antagonistic tetrapeptide Z-VRPRFMK impairs optimal NF-κB activation and interleukin-2 (IL-2) production.28,29 In addition, one MALT1 inhibitor (JNJ-67856633) is undergoing phase 1 clinical trials.30 These observations suggest that MALT1 represents a potential therapeutic target for ATL. In this study, we identified a small-molecule inhibitor of MALT1 and evaluated its effects on ATL cells in vitro and in vivo. Results Identification of a potent and highly selective MALT1 inhibitor, CRD-1441551 We discovered a highly potent, orally available MALT1 inhibitor, CRD-1441551 (S)-(1-(5-chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(8-(1-methoxyethyl)-2-methylimidazo[1,2-b]pyridazin-7-yl)urea) (Figure 1A). Details of the synthetic route to this compound are described in Figure S1 and Table S1. CRD-1441551 potently inhibited the enzymatic activity of MALT1 protease with a half-maximal inhibitory concentration (IC50) of 33.5 nmol/L (Figure 1B). Additionally, a protease selectivity assay utilizing panel screening revealed the high selectivity of CRD-1441551 against 57 tested proteases at a screening concentration of 3 μmol/L, which is more than 100-fold greater than the measured IC50 of CRD-1441551 in a MALT1 biochemical assay (Figure 1C). No significant responses (≥50% inhibition or stimulation) were observed, indicating its high selectivity against MALT1. Kinetic profiling and interaction analyses of CRD-1441551 with MALT1 protein revealed that the dissociation rate constant (KD) value was 40.3 nmol/L (Figure 1D), which is consistent with the IC50 value of 33.5 nmol/L for MALT1 protease inhibition (Figure 1B). Moreover, the dissociation half-life (t1/2) after binding to the recombinant MALT1 protein was only 3.8 min (Figure 1E). The highly reversible binding of CRD-1441551 to MALT1 in OCI-Ly3 cells was confirmed by washout experiments (Figure S2). The amount of cleaved BCL10 (cBCL10), an indicator of the cellular paracaspase activity of MALT1, recovered to the baseline level 2 h after CRD-1441551 washout. Two conserved MALT1 splice variants, MALT1A and MALT1B, exist in mammals, and the balance between their expression determines the downstream effects on NF-κB.31 The inhibitory activity of CRD-1441551 on the protease activity of both variants was confirmed by decreased expression of cBCL10 (Figure S3A). NF-κB transcriptional activity was evaluated using a luciferase reporter assay in 293T cells, which demonstrated that MALT1 inhibition partially suppresses NF-κB-dependent transcription (Figure S3B). Finally, the pharmacokinetic parameters in mice were evaluated, and the area under the curve from time 0 to 48 h (AUC0–48h) of CRD-1441551 was 5.222 (μg h/mL) (Figure S4). These results indicate that CRD-1441551 is a highly potent, selective, and reversible MALT1 inhibitor.Figure 1Generation of a potent and highly selective MALT1 inhibitor, CRD-1441551(A) Chemical structure of CRD-1441551. Synthetic method and route are described in Figure S1 and Table S1.(B) Potent inhibition of MALT1 by CRD-1441551. IC50 value of CRD-1441551 for purified recombinant MALT1 protein was determined by enzymatic assay. The x and y axes represent CRD-1441551 concentration and the percentage of inhibition of MALT1, respectively. Data represent mean ± standard deviation for each concentration (n = 3).(C) Highly selective inhibition of MALT1 by CRD-1441551. The percentage of inhibition of enzymatic activity for approximately 60 proteases, including MALT1, was determined by panel screening. Three micromolar CRD-1441551 was applied in each enzymatic assay, performed in duplicate. The x and y axes represent each protease and the percent inhibition for each protease, respectively. Positive or negative percent inhibition values indicate inhibition or promotion of the activity of each protease.(D) Binding kinetics of CRD-1441551 to MALT1. The KD value for the recombinant His-LZ-MALT1 recombinant protein was determined by affinity selection–mass spectrometry (AS-MS) direct binding assay. Specific binding was calculated by subtraction of nonspecific binding from total binding. Data represent mean ± SD for each concentration (n = 3).(E) Dissociation kinetics of CRD-1441551 from MALT1 determined by AS-MS. Dissociation half-life (t1/2) was calculated as described in the STAR Methods.See also Figures S2, S3, and S4 Generation of a potent and highly selective MALT1 inhibitor, CRD-1441551 (A) Chemical structure of CRD-1441551. Synthetic method and route are described in Figure S1 and Table S1. (B) Potent inhibition of MALT1 by CRD-1441551. IC50 value of CRD-1441551 for purified recombinant MALT1 protein was determined by enzymatic assay. The x and y axes represent CRD-1441551 concentration and the percentage of inhibition of MALT1, respectively. Data represent mean ± standard deviation for each concentration (n = 3). (C) Highly selective inhibition of MALT1 by CRD-1441551. The percentage of inhibition of enzymatic activity for approximately 60 proteases, including MALT1, was determined by panel screening. Three micromolar CRD-1441551 was applied in each enzymatic assay, performed in duplicate. The x and y axes represent each protease and the percent inhibition for each protease, respectively. Positive or negative percent inhibition values indicate inhibition or promotion of the activity of each protease. (D) Binding kinetics of CRD-1441551 to MALT1. The KD value for the recombinant His-LZ-MALT1 recombinant protein was determined by affinity selection–mass spectrometry (AS-MS) direct binding assay. Specific binding was calculated by subtraction of nonspecific binding from total binding. Data represent mean ± SD for each concentration (n = 3). (E) Dissociation kinetics of CRD-1441551 from MALT1 determined by AS-MS. Dissociation half-life (t1/2) was calculated as described in the STAR Methods. See also Figures S2, S3, and S4 Antitumor activity of CRD-1441551 in vitro and in vivo MALT1 is located downstream of the TCR signaling pathway and contributes to cell survival following TCR activation.32,33 Three ATL cell lines, LM-Y1, LM-Y2, and S1T, had at least one gene alteration in the TCR pathway (Figures 2A and S5; Table S2) and expressed cBCL10 protein, indicating the activation of MALT1 protease activity across all three cell lines, albeit minimal in LM-Y1 cells (Figure 2B; Table S3). CRD-1441551 treatment was associated with decreased amounts of cBCL10 in LM-Y1, LM-Y2, and S1T cells, with IC50 values of 6.9, 10, and 18 nmol/L, respectively. RelB, CYLD, and HOIL-1 are established substrates of the MALT1 protease activity. CRD-1441551 treatment increased RelB expression in LM-Y2 and S1T cells. In these cells, the expressions of cleaved CYLD and cleaved HOIL-1 were decreased, accompanied by accumulation of total CYLD and total HOIL-1. In contrast, these effects were not observed in LM-Y1 cells following CRD-1441551 treatment.Figure 2Cellular mechanism of CRD-1441551 in ATL cell line models(A) Overview of somatic alterations in ATL cell lines. Each column and row correspond to an ATL cell line and an altered gene, respectively. The type of alteration is indicated by color and described in the legend. Detailed plots of TCR pathway mutations are shown in Figure S5 and Table S2.(B) Protein expression of cleaved BCL10, components of the CBM complex, RelB, cleaved CYLD, total CYLD, cleaved HOIL-1, and total HOIL-1 in ATL cell lines. Cell lysates from ATL cell lines treated with the indicated concentrations of CRD-1441551 for 24 h were analyzed by western blotting. Band intensities were quantified, normalized to control levels, and presented as percentage values in the accompanying bar graph.See also Table S3. Cellular mechanism of CRD-1441551 in ATL cell line models (A) Overview of somatic alterations in ATL cell lines. Each column and row correspond to an ATL cell line and an altered gene, respectively. The type of alteration is indicated by color and described in the legend. Detailed plots of TCR pathway mutations are shown in Figure S5 and Table S2. (B) Protein expression of cleaved BCL10, components of the CBM complex, RelB, cleaved CYLD, total CYLD, cleaved HOIL-1, and total HOIL-1 in ATL cell lines. Cell lysates from ATL cell lines treated with the indicated concentrations of CRD-1441551 for 24 h were analyzed by western blotting. Band intensities were quantified, normalized to control levels, and presented as percentage values in the accompanying bar graph. See also Table S3. Next, we investigated the ability of CRD-1441551 to inhibit the growth of ATL cell lines with MALT1 activity in vitro. The concentrations of CRD-1441551 causing 50% growth inhibition (GI50) were 20.4, 0.8, and 15.7 μmol/L in LM-Y1, LM-Y2, and S1T cells, respectively (Figure 3A). Consistently, CRD-1441551 induced apoptosis in LM-Y2 cells. As shown in Figure 3B, cleaved caspase-3 and -7 were induced after 72 h of treatment in LM-Y2 cells. These markers were also detected in LM-Y1 cells; however, the magnitude of induction was lower than that observed in LM-Y2 cells.Figure 3In vitro and in vivo antitumor effects of CRD-1441551 on ATL cell lines with MALT1 activation(A) In vitro antigrowth effect of CRD-1441551 on three ATL cell lines with MALT1 activation. Cell viability was measured after a 6-day exposure. GI50 values were calculated. Data represent mean ± SD (n = 3), which were confirmed in two independent experiments.(B) Western blot analysis of cleaved caspase-3 and cleaved caspase-7 in LM-Y1 and LM-Y2 cells. Cells were treated with 10-5 M CRD-1441551 for the indicated durations.(C) Tumor growth in an S1T xenograft model during CRD-1441551 treatment. Mice were treated for 14 consecutive days with CRD-1441551 at dosages of 60 or 100 mg/kg twice daily, lenalidomide at a dosage of 30 mg/kg once daily, or vehicle. Data represent mean ± SD (n = 6 per group). See also Figure S6.(D) Protein expression of cBCL10, components of the CBM complex, RelB, and IRF4 in S1T xenograft tumors. Tumor lysates were prepared 8 h after a single administration of CRD-1441551 and subjected to western blotting. Band intensities were quantified, normalized to control levels, and presented as percentage values in the accompanying bar graph. Data represent mean ± SD (n = 3 per group). In vitro and in vivo antitumor effects of CRD-1441551 on ATL cell lines with MALT1 activation (A) In vitro antigrowth effect of CRD-1441551 on three ATL cell lines with MALT1 activation. Cell viability was measured after a 6-day exposure. GI50 values were calculated. Data represent mean ± SD (n = 3), which were confirmed in two independent experiments. (B) Western blot analysis of cleaved caspase-3 and cleaved caspase-7 in LM-Y1 and LM-Y2 cells. Cells were treated with 10-5 M CRD-1441551 for the indicated durations. (C) Tumor growth in an S1T xenograft model during CRD-1441551 treatment. Mice were treated for 14 consecutive days with CRD-1441551 at dosages of 60 or 100 mg/kg twice daily, lenalidomide at a dosage of 30 mg/kg once daily, or vehicle. Data represent mean ± SD (n = 6 per group). See also Figure S6. (D) Protein expression of cBCL10, components of the CBM complex, RelB, and IRF4 in S1T xenograft tumors. Tumor lysates were prepared 8 h after a single administration of CRD-1441551 and subjected to western blotting. Band intensities were quantified, normalized to control levels, and presented as percentage values in the accompanying bar graph. Data represent mean ± SD (n = 3 per group). For in vivo evaluation of the effect of CRD-1441551 on ATL cells, the three cell lines with MALT1 activity were transplanted into NOD/Shi-scid, IL-2Rγnull (NOG) mice. Only the S1T cell line demonstrated tumorigenesis and growth in vivo. S1T cell growth in transplanted mice was inhibited by CRD-1441551, but only minimally by lenalidomide, an approved medication against ATL (Figure 3C). Orally administered CRD-1441551 did not cause severe body weight loss in recipient mice (Figure S6). In this model, administration of CRD-1441551 induced an increase in RelB protein expression and downregulated IRF4 protein expression in xenograft tumor tissue (Figure 3D). Taken together, CRD-1441551 exerted antitumor activity in an ATL cell line model in vitro and in vivo. Establishment of ATL patient-derived xenograft models and evaluation of the antitumor activity of CRD-1441551 Patient-derived xenograft (PDX) models are expected to accurately predict therapeutic efficacy because they recapitulate various aspects of the complexity of human cancer, including tumor heterogeneity, cellular lineage hierarchy, and tumor-stroma interaction. Therefore, we established ATL PDX models in this study. Primary lymph node or peripheral blood samples from 20 patients with ATL were transplanted into NOG mice, and successful engraftment of samples from five patients with ATL was achieved (Table S4), resulting in tumor growth. Tumors grew successfully in NOG mice following transplantation. These PDX models demonstrated the pathological features of the tumors, as shown in Figure S7. Cells exhibited pleomorphic features and were positive for human CD4. Gene mutation profiles of tumor cells from PDX models were obtained. Three of the five models possessed one or more TCR pathway mutations (Figures 4A and S5). Next, we evaluated the activation level of MALT1 in the five PDX models by detecting cBCL10. As shown in Figure 4B, the M67, M143, and M156 models expressed cBCL10, but the M153 and M164 models did not, indicating that MALT1 was activated in the M67, M143, and M156 models but not in the other models. M67 and M156 harbored PRKCB and/or CARD11 mutations, suggesting that these mutations in TCR signaling molecules might induce MALT1 activation. In contrast, there were no TCR signaling pathway mutations in the M143 PDX model, which indicated that other pathways might activate MALT1.Figure 4CRD-1441551 suppresses ATL PDX tumors(A) Overview of somatic mutations in established five PDX tumors. Each column and row correspond to a PDX model and mutated gene, respectively. Detailed plots of TCR pathway mutations are shown in Figure S5.(B) Inhibition of MALT1 paracaspase activity by CRD-1441551 and related effects on PDX tumors. Tumor lysates were prepared after the efficacy study and subjected to western blotting. Representative results of western blotting are shown (n = 2 per treatment group in each PDX model). The band intensities of IRF4 were quantified (n = 2 per treatment group in each PDX model), and the percent IRF4 inhibition by CRD-1441551 treatment is shown in bar charts. Reduction of cBCL10 and IRF4 and accumulation of RelB were observed following CRD-1441551 treatment in three models (M67, M143, and M156).(C) Suppression of PDX tumors by CRD-1441551. Recipient mice with 300‑600 mm3 tumors were treated twice daily with 60 mg/kg CRD-1441551 or vehicle for 21 days or 12 days for the M153 model. Tumor growth in each PDX model was assessed every 3–4 days during CRD-1441551 treatment. Growth suppression was observed in PDX tumors, M67, M143, and M156. Data represent mean ± SD (n = 5 per group). Two-way ANOVA followed by Tukey’s post hoc test was performed, p < 0.05 or p < 0.01 are shown by ∗ or ∗∗, respectively.(D) Histology of tumor tissue in the five PDX models. Microscopic views of samples stained with Ki-67 are shown at high magnification (×400). Scale bars, 50 μm. The frequency of Ki-67-positive cells was assessed (five high-power fields per tumor) and shown in a bar chart. Data represent mean frequency ±SD (n = 5 per treatment group in each PDX model). A paired Student’s t test was performed, and p < 0.05 is shown by ∗.(E) Serum LDH and human sIL-2R levels after treatment. Recipient mice transplanted with the M67 PDX clone showed decreased levels of LDH and human sIL-2R after CRD-1441551 treatment. Data represent mean ± SD (n = 5 per group). A paired Student’s t test was performed, and p < 0.05 or p < 0.01 are shown by ∗ or ∗∗, respectively.See also Figure S7, S8, and Table S4. CRD-1441551 suppresses ATL PDX tumors (A) Overview of somatic mutations in established five PDX tumors. Each column and row correspond to a PDX model and mutated gene, respectively. Detailed plots of TCR pathway mutations are shown in Figure S5. (B) Inhibition of MALT1 paracaspase activity by CRD-1441551 and related effects on PDX tumors. Tumor lysates were prepared after the efficacy study and subjected to western blotting. Representative results of western blotting are shown (n = 2 per treatment group in each PDX model). The band intensities of IRF4 were quantified (n = 2 per treatment group in each PDX model), and the percent IRF4 inhibition by CRD-1441551 treatment is shown in bar charts. Reduction of cBCL10 and IRF4 and accumulation of RelB were observed following CRD-1441551 treatment in three models (M67, M143, and M156). (C) Suppression of PDX tumors by CRD-1441551. Recipient mice with 300‑600 mm3 tumors were treated twice daily with 60 mg/kg CRD-1441551 or vehicle for 21 days or 12 days for the M153 model. Tumor growth in each PDX model was assessed every 3–4 days during CRD-1441551 treatment. Growth suppression was observed in PDX tumors, M67, M143, and M156. Data represent mean ± SD (n = 5 per group). Two-way ANOVA followed by Tukey’s post hoc test was performed, p < 0.05 or p < 0.01 are shown by ∗ or ∗∗, respectively. (D) Histology of tumor tissue in the five PDX models. Microscopic views of samples stained with Ki-67 are shown at high magnification (×400). Scale bars, 50 μm. The frequency of Ki-67-positive cells was assessed (five high-power fields per tumor) and shown in a bar chart. Data represent mean frequency ±SD (n = 5 per treatment group in each PDX model). A paired Student’s t test was performed, and p < 0.05 is shown by ∗. (E) Serum LDH and human sIL-2R levels after treatment. Recipient mice transplanted with the M67 PDX clone showed decreased levels of LDH and human sIL-2R after CRD-1441551 treatment. Data represent mean ± SD (n = 5 per group). A paired Student’s t test was performed, and p < 0.05 or p < 0.01 are shown by ∗ or ∗∗, respectively. See also Figure S7, S8, and Table S4. We next used these PDX models to perform an in vivo efficacy assessment of CRD-1441551. Antitumor efficacy could be clearly seen in the M67 PDX model and, to a lesser extent, in the M143 and M156 models, but not in the M153 and M164 models with inactive MALT1 (Figure 4C). An obvious antitumor effect was observed in the M67 model by monitoring tumor size and counting the number of Ki67-positive cells, which reflects cell proliferation (Figure 4D). M67 PDX clone-bearing NOG mice that demonstrated shrinking of ATL tumors following CRD-1441551 treatment also exhibited drastic decreases in the serum levels of lactate dehydrogenase (LDH) (p < 0.05) and human sIL-2R (p < 0.01) (Figure 4E). Furthermore, we performed a more detailed analysis of the M67 PDX model to clarify the effects of CRD-1441551 on ATL pathology. The engrafted M67 PDX clone not only induced the development of subcutaneous tumors but also facilitated the invasion of the lung, spleen, liver, kidney, and bone marrow (BM) (Figure S8). In vehicle-treated NOG mice engrafted with the M67 PDX clone, the alveolar interstitium and septa were thickened by infiltrating ATL cells, and the area of the normal alveolar cavity was decreased. Moreover, aggressive ATL cell invasion was observed in the liver and spleen, and the normal architectures of these organs were destroyed. However, CRD-1441551 administration eliminated the ATL cells in these organs and restored their architectures. Interstitial infiltration of ATL cells was observed in the kidney of vehicle-treated NOG mice with M67 PDX, and renal lesions disappeared in mice treated with CRD-1441551. Focal infiltration of ATL cells in BM was observed in vehicle-treated NOG mice with M67 PDX, and ATL cells comprised 50.7% ± 13.8% of all BM nucleated cells. CRD-1441551 treatment drastically reduced the percentage of infiltrating ATL cells in BM to 3.93% ± 2.6% (p = 0.0021). In accordance with the ability of CRD-1441551 to inhibit the growth of the M67 clone, RelB protein accumulation (a competitor for DNA binding with the RelA and c-Rel complex) as well as decreased amounts of intratumoral IRF4 protein were observed (Figure 4B). Taken together, CRD-1441551 showed an antitumor effect in ATL PDX models with MALT1 activation. In addition, the tumor activity of some PDX models with MALT1 activation was partially dependent on the MALT1 activation signaling cascade and its downstream effects. Signaling pathway analysis in ATL cell lines and PDX models Although MALT1 activation, as indicated by BCL10 cleavage, was associated with sensitivity to MALT1 inhibition, it was insufficient to predict the magnitude of response. While inhibition of BCL10 cleavage confirmed effective target engagement, only a subset of models exhibited significant tumor growth suppression, indicating that additional molecular determinants influence therapeutic response. To further investigate these determinants, we performed gene expression profiling focusing on downstream signaling outputs of MALT1. We defined a gene signature representing MALT1-driven NF-κB-dependent proliferation and survival signals, including canonical NF-κB target genes (e.g., NFKBIZ and NFKBID), MALT1 paracaspase-dependent genes (e.g., ZC3H12A/Regnase-1), and T cell activation and proliferation markers (e.g., IRF4, MYC, ICOS, and CTLA4).34,35,36 Under vehicle treatment, this MALT1-NF-κB output signature was enriched in sensitive models (LM-Y2 and PDX M67) but not in unresponsive models (LM-Y1, PDX M153, and PDX M164) (Figure 5A). Upon CRD-1441551 treatment, this signature was significantly suppressed in sensitive models (Figure 5B), supporting its relevance as a functional readout of MALT1 dependency.Figure 5MALT1-dependent NF-κB target activation contributes to sensitivity to MALT1 inhibition(A) Heatmap showing single-sample gene set enrichment analysis (ssGSEA) scores for the MALT1-dependent NF-κB target gene set and the IRF4 target program in ATL cell lines and PDX models under vehicle treatment. ssGSEA enrichment scores were row-normalized (Z-scored) within each panel (cell lines and PDX models analyzed separately). Treatment responses are indicated as sensitive (blue), partially responsive (orange), and unresponsive (red). Sensitive models exhibited higher MALT1-dependent NF-κB target scores.(B) Gene set enrichment analysis (GSEA) of the MALT1-dependent NF-κB target gene set and IRF4 target program following CRD-1441551 treatment. Enrichment plots display the running enrichment score (ES; y axis) across the ranked gene list (x axis). Normalized enrichment scores (NES) and nominal p values are shown. Asterisks (∗) indicate gene sets significantly downregulated upon CRD-1441551 treatment (NES <0, p < 0.05), whereas hash symbols (#) indicate gene sets significantly upregulated (NES > 0, p < 0.05). Both MALT1-dependent NF-κB target and IRF4 target gene sets were consistently downregulated in sensitive models (LM-Y2 and M67). MALT1-dependent NF-κB target activation contributes to sensitivity to MALT1 inhibition (A) Heatmap showing single-sample gene set enrichment analysis (ssGSEA) scores for the MALT1-dependent NF-κB target gene set and the IRF4 target program in ATL cell lines and PDX models under vehicle treatment. ssGSEA enrichment scores were row-normalized (Z-scored) within each panel (cell lines and PDX models analyzed separately). Treatment responses are indicated as sensitive (blue), partially responsive (orange), and unresponsive (red). Sensitive models exhibited higher MALT1-dependent NF-κB target scores. (B) Gene set enrichment analysis (GSEA) of the MALT1-dependent NF-κB target gene set and IRF4 target program following CRD-1441551 treatment. Enrichment plots display the running enrichment score (ES; y axis) across the ranked gene list (x axis). Normalized enrichment scores (NES) and nominal p values are shown. Asterisks (∗) indicate gene sets significantly downregulated upon CRD-1441551 treatment (NES <0, p < 0.05), whereas hash symbols (#) indicate gene sets significantly upregulated (NES > 0, p < 0.05). Both MALT1-dependent NF-κB target and IRF4 target gene sets were consistently downregulated in sensitive models (LM-Y2 and M67). To further investigate mechanisms of unresponsiveness, we analyzed additional signaling pathways associated with cell survival and proliferation. Although no single pathway was consistently activated across all unresponsive models, individual models exhibited increased reliance on distinct pathways, including mTOR, JAK/STAT, and Hedgehog signaling. These findings suggest that unresponsiveness to CRD-1441551 may arise through heterogeneous, model-specific pathway dependencies. Discussion In this study, we developed CRD-1441551, an orally available small molecule that selectively and potently inhibits MALT1. CRD-1441551 inhibited ATL cell growth in ATL cell lines and ATL PDX models with constitutive activation of MALT1, even though its magnitude differed among cells. CRD-1441551 inhibited the enzymatic activity of MALT1 protease with an IC50 value of 33.5 nmol/L and exhibited high selectivity against MALT1. A previous study by Ishikawa and Mori identified MALT1 as a potential therapeutic target; however, their analysis was limited to two ATL cell lines.37 Notably, the MALT1 inhibitor MI-2 also disrupts MALT1-independent PI3K/AKT and MAPK/ERK signaling pathways38,39,40 and has been reported to induce ferroptosis independently of MALT1.41 Therefore, the effectiveness of selective MALT1 inhibition remains unclear in a more diverse set of ATL samples. We evaluated the efficacy of CRD-1441551 against ATL cell lines and PDX clones. To establish a foundational framework for the use of precision medicine in ATL using CRD-1441551, we examined both mutational status and MALT1 activity across these samples. PLCG1, PRKCB, and CARD11 alterations are present in approximately 70% of patients with ATL and have been implicated in NF-κB activation.13,14 However, MALT1 activation was not uniformly observed in PDX models harboring these mutations. Even among models carrying the same PRKCB D427N mutation, MALT1 activation status differed, indicating that this mutation alone is insufficient to drive constitutive MALT1 activation. These findings suggest that MALT1 activation is not determined by individual mutations but instead depends on the broader signaling context, including CBM complex integrity. Although CRD-1441551 effectively suppressed MALT1 protease activity, its downstream effects on NF-κB signaling were incomplete in certain contexts. In a 293T overexpression system, NF-κB activity was only partially reduced, likely reflecting the nonphysiological conditions in which strong ectopic expression sustains signaling independently of MALT1 protease activity. Consistent with this observation, the degree of suppression of MALT1-NF-κB signaling by CRD-1441551 varied across ATL cell lines and PDX models. CRD-1441551 treatment was also associated with increased expression of RelB and NF-κB regulatory factors, including CYLD and HOIL-1, suggesting activation of compensatory mechanisms such as noncanonical NF-κB signaling or feedback regulation. In addition, posttranscriptional regulation mediated by MALT1 substrates, including Regnase-1 and Roquin-1, may further influence cellular responses.21,22 All ATL cell lines and PDX models exhibiting constitutive MALT1 activation showed some degree of response to CRD-1441551, although the magnitude varied. These findings support the concept that therapeutic efficacy depends on the extent of reliance on the MALT1-NF-κB axis. The MALT1-NF-κB output signature identified sensitive models, and its suppression by CRD-1441551 correlated with therapeutic efficacy. In contrast, unresponsive models demonstrated reduced dependence on this pathway and instead exhibited heterogeneous activation of alternative signaling pathways, including mTOR, JAK/STAT, and Hedgehog signaling. These observations highlight the heterogeneity of signaling dependencies in ATL, wherein tumors driven by the MALT1-NF-κB axis are sensitive to CRD-1441551, whereas those relying on alternative pathways are relatively resistant. ATL is a biologically heterogeneous disease, and currently available therapies—including mogamulizumab, tucidinostat, and valemetostat—do not achieve durable responses in all patients despite their clinical activity.8,10,11 Reported overall response rates are approximately 50%, with median progression-free survival of ∼7, 4, and 8 months for mogamulizumab, tucidinostat, and valemetostat, respectively.42,43,44 In this context, MALT1 inhibition represents a mechanistically distinct therapeutic strategy with selective antitumor activity in a subset of ATL models. Although efficacy is not universal, this selectivity likely reflects underlying biological dependencies and may be leveraged for biomarker-driven patient stratification. Our findings provide a mechanistic basis for such stratification by linking MALT1-NF-κB dependency to therapeutic sensitivity. Treatments that confer meaningful benefit in biologically defined patient subsets remain clinically valuable in ATL. In conclusion, we developed a potent and selective MALT1 inhibitor and demonstrated that a subset of ATL depends on constitutive MALT1 activation for tumorigenicity. These findings indicate that MALT1 inhibition may represent an effective therapeutic strategy for biologically defined patient subgroups. Limitations of the study We did not perform genetic validation of MALT1 dependency in CRD-1441551-sensitive ATL cell lines or PDX models, such as knockdown or knockout approaches. Therefore, we cannot formally exclude the possibility that the observed antitumor effects are influenced by off-target activities. However, CRD-1441551 exhibits high selectivity toward MALT1, suggesting that off-target effects are unlikely to be the primary driver of the observed phenotypes. The limited number of PDX models precludes definitive conclusions regarding the role of MALT1-NF-κB signaling in mediating sensitivity to CRD-1441551. Regarding the safety profile of CRD-1441551, no major safety liabilities were identified in preliminary in vitro screening assays. However, further studies are required to comprehensively evaluate its safety. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Kazuya Shimoda (kshimoda@med.miyazaki-u.ac.jp). Materials availability CRD-1441551 was generated in this study. Detailed information on its synthesis is provided in Table S1. All other reagents used in this study are commercially available and listed in the key resources table. CRD-1441551 generated in this study will be made available on request, but we may require a payment and/or a completed materials transfer agreement if there is potential for commercial application. Data and code availability •RNA-seq data from ATL cell lines have been deposited at the DNA DataBank of Japan (DDBJ) Sequence Read Archive and are publicly available as of the date of publication (DDBJ: PRJDB42075). RNA-seq data from ATL PDX models have been deposited at the Japanese Genotype-phenotype Archive (JGA) and are available under controlled access (JGA: JGAS000921). The X-ray crystallographic data for compound 18 (CRD-1441551) have been deposited at the Cambridge Crystallographic Data Centre and are publicly available as of the date of publication (CCDC: CCDC 2561470).•This paper does not report original code.•Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. •RNA-seq data from ATL cell lines have been deposited at the DNA DataBank of Japan (DDBJ) Sequence Read Archive and are publicly available as of the date of publication (DDBJ: PRJDB42075). RNA-seq data from ATL PDX models have been deposited at the Japanese Genotype-phenotype Archive (JGA) and are available under controlled access (JGA: JGAS000921). The X-ray crystallographic data for compound 18 (CRD-1441551) have been deposited at the Cambridge Crystallographic Data Centre and are publicly available as of the date of publication (CCDC: CCDC 2561470). RNA-seq data from ATL cell lines have been deposited at the DNA DataBank of Japan (DDBJ) Sequence Read Archive and are publicly available as of the date of publication (DDBJ: PRJDB42075). RNA-seq data from ATL PDX models have been deposited at the Japanese Genotype-phenotype Archive (JGA) and are available under controlled access (JGA: JGAS000921). The X-ray crystallographic data for compound 18 (CRD-1441551) have been deposited at the Cambridge Crystallographic Data Centre and are publicly available as of the date of publication (CCDC: CCDC 2561470). •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments The authors thank S. Saitou, M. Matsushita, and T. Shinmori for their technical assistance. The authors also thank Naomi Inui for her technical and clerical work. This research was supported by the following grants from the Japan Agency for Medical Research and Development: JP22ck0106538, and JP23ck0106789 to K. Shimoda; JP18im0210102 to D.M.; JP18im0210102 to S.O.; and JSPS KAKENHI (26K02444) to K. Shimoda. This study was supported by the Frontier Science Research Center, University of Miyazaki. Supercomputing resources were provided by the Human Genome Center, the Institute of Medical Science, and the University of Tokyo. Author contributions D.M., S.O., and K. Shimoda were involved in the conception, design, and planning of the study; D.M., M. Sugiyama, S.E., A.M., T. Hirayama, T. Kawamoto, H.T., T.T., H.B., Y.A., T.M., and H.O. developed CRD-1441551 and evaluated its characteristics; A.K., D.M., T. Kameda, M. Sugiyama, S.E., A.M., K. Shide, Y.A., H.H., Y.I., J.-i.Y., M.M., K.I., and K.K. performed cell line experiments; A.K., T. Kameda, K. Shide, Y.T., K.A., M. Sekine, H.S., T. Hidaka, Y. Kubuki, and H.Y. performed primary ATL cell experiments; R.I., K.M., M.K., A.K., D.M., T. Kameda, M. Sugiyama, S.E., Y. Kogure, A.M., Y.O., K. Shide, Y.A., A.Y., K.K., S.O., and K. Shimoda performed xenograft experiments; Y. Kogure, K.K., and S.O. performed targeted capture sequencing; A.K., T. Kameda, Y. Kogure, Y.O., and S.O. performed gene expression analysis; A.K., D.M., T. Kameda, S.O., and K. Shimoda guided the analysis and interpretation and wrote the first draft of the manuscript. All authors reviewed the drafts and final version of the manuscript and agreed with its content and submission. K. Shimoda held the final responsibility for the decision to submit this manuscript for publication. Declaration of interests K. Shimoda has received consulting fees from Novartis Pharma, Takeda Pharmaceutical, and Bristol-Myers, all outside the submitted work, and has received research grants from Perseus Proteomics, PharmaEssentia Japan KK, AbbVie GK, Astellas Pharma, MSD, Chugai Pharmaceutical, Kyowa Kirin, Pfizer, Novartis Pharma, Otsuka Pharmaceutical, and Asahi Kasei Medical, all outside the submitted work. D.M., A.M., and Y.A. are employees of and hold stock in Chordia Therapeutics Inc. M. Sugiyama and S.E. are employees of Chordia Therapeutics Inc. K.K. holds stock in Asahi Genomics, has a patent for genetic alterations as a biomarker in T cell lymphomas, and has received research funding from Chordia Therapeutics outside the submitted work. Y. Kogure has received personal fees from Takeda Pharmaceutical, outside of the submitted work. Y.I. has received honoraria from Kyowa Kirin, Celgene, Bristol-Myers Squibb, Eisai, Sanofi, Sumitomo Dainippon Pharma, SymBio Pharmaceuticals, Meiji Seika Pharma, Chugai Pharmaceutical, and Nippon Shinyaku, all outside the submission. K.I. has received research grants from Ono Pharmaceutical and Kyowa Kirin; consulting fees from Daiichi Sankyo; and honoraria from Chugai Pharmaceutical, Celgene, and Kyowa Kirin, all outside the submitted work. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit Anti-cleaved BCL10This studyN/ARabbit Anti-Bcl10 (C78F1)Cell Signaling Technology#4237, RRID:AB_2228005Rabbit Anti-MALT1Cell Signaling Technology#2494, RRID:AB_2139139Rabbit Anti-CARD11 (1D12)Cell Signaling Technology#4435, RRID:AB_2070359Rabbit Anti-RelB (C1E4)Cell Signaling Technology#4922, RRID:AB_2179173Rabbit Anti-IRF4 (D43H10)Cell Signaling Technology#4299, RRID:AB_10547141Rabbit Anti-CYLD (D1A10)Cell Signaling Technology#8462, RRID:AB_10891754Rabbit Anti-RBCK1/HOIL-1 (polyclone)Sigma-AldrichHPA024185, RRID:AB_1846237Rabbit Anti-Cleaved Caspase-3 (Asp175)Cell Signaling Technology#9661, RRID:AB_2341188Rabbit Anti-Cleaved Caspase-7 (Asp198)Cell Signaling Technology#9491, RRID:AB_2075144Rabbit Anti-β-Actin (13E5) HRP conjugatedCell Signaling Technology#5125, RRID:AB_1903890Goat Anti-Rabbit IgG HRP linked (secondary antibody)Cell Signaling Technology#7074 S, RRID:AB_2099233Horse Anti-Mouse IgG HRP linked (secondary antibody)Cell Signaling Technology#7076 S, RRID:AB_330924Rabbit Anti-CD4Abcam#ab133616, RRID:AB_2750883Rabbit Anti-Mouse/Human Ki-67Abcam#ab15580, RRID:AB_443209Normal Mouse IgGSanta Cruz BiotechnologyCat#sc-2025; RRID: AB_737182Mouse Anti-MALT1Santa Cruz BiotechnologyCat#sc-46677; RRID: AB_627909Biological samplesPrimary ATL patient samples (peripheral blood and lymph node)This studyEthics approval G-0010, G-1116, 2015-146Chemicals, peptides, and recombinant proteinsCRD-1441551This studyN/ALenalidomideFujifilm#120-06731Ac-LRSR-AFCSM Biochemicals LLC#SMAFC013Recombinant human IL-2Kyowa Pharmaceutical IndustryN/ARPMI 1640 MediumThermoFisher Scientific#11875500BTPenicillin-Streptomycin (100 U/mL Penicillin, 100 μg/mL Streptomycin)Fujifilm WakoCat#168-23191; JAN4987481473331Hank’s Balanced Salt SolutionThermoFisher Scientific#14170112BD Matrigel™ MatrixBD Biosciences#3562310.5% Methylcellulose (vehicle for in vivo dosing)N/AN/ACritical commercial assaysCellTiter-Glo® 2.0 Cell Viability AssayPromega#G9242SureSelect Custom KitAgilent TechnologiesN/AQuantiChrom™ Lactate Dehydrogenase KitBioAssay Systems#D2DH-100Human CD25/IL-2Rα Quantikine ELISA KitR&D Systems#DR2A00Protease selectivity panelEurofins PanlabsN/ADeposited dataGene expression (RNA-seq) from ATL cell linesThis studyDDBJ: PRJDB42075Gene expression (RNA-seq) from ATL PDX modelsThis studyJGA: JGAS000921Crystal structure of CRD-1441551This studyCCDC: 2561470Experimental models: Cell linesLM-Y1Dr. Hasegawa, Nagasaki UniversityCVCL_VN50LM-Y2Dr. Hasegawa, Nagasaki UniversityCVCL_VN51S1TDr. Ishitsuka, Kagoshima UniversityCVCL_1687OCI-Ly3ATCC#CRL-2631HEK293TATCC#CRL-3216Experimental models: Organisms/strainsMouse: NOD/Shi-scid, IL-2Rγnull (NOG)Central Institute for Experimental AnimalsN/AATL cell line xenograft (PDX)This studyN/AATL patient-derived xenograft (PDX)This studyN/ARecombinant DNAHis-LZ–MALT1 expression constructThis studyN/ABCL10 expression constructThis studyN/ACARD11 expression constructThis studyN/AMALT1A expression constructThis studyN/AMALT1B expression constructThis studyN/ANF-κB reporter (firefly luciferase) plasmidN/AN/ATK reporter (Renilla luciferase) plasmidN/AN/ASoftware and algorithmsGraphPad Prism 6GraphPad Softwarehttps://www.graphpad.com/API-5000 LC/MS/MSAB SciexN/AR version 4.0.3R Core Teamwww.r-project.orgGSVA R packageBioconductorhttps://bioconductor.org/packages/GSVA/fgsea R packageBioconductorhttps://bioconductor.org/packages/fgsea/Genomon pipelineGitHubhttps://github.com/Genomon-Project/Integrative Genomics ViewerBroad Institutehttps://software.broadinstitute.org/software/igv/; RRID:SCR_011793OtherBioruptorCosmo Bio Co., Ltd.Cat#UCW-310 REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit Anti-cleaved BCL10This studyN/ARabbit Anti-Bcl10 (C78F1)Cell Signaling Technology#4237, RRID:AB_2228005Rabbit Anti-MALT1Cell Signaling Technology#2494, RRID:AB_2139139Rabbit Anti-CARD11 (1D12)Cell Signaling Technology#4435, RRID:AB_2070359Rabbit Anti-RelB (C1E4)Cell Signaling Technology#4922, RRID:AB_2179173Rabbit Anti-IRF4 (D43H10)Cell Signaling Technology#4299, RRID:AB_10547141Rabbit Anti-CYLD (D1A10)Cell Signaling Technology#8462, RRID:AB_10891754Rabbit Anti-RBCK1/HOIL-1 (polyclone)Sigma-AldrichHPA024185, RRID:AB_1846237Rabbit Anti-Cleaved Caspase-3 (Asp175)Cell Signaling Technology#9661, RRID:AB_2341188Rabbit Anti-Cleaved Caspase-7 (Asp198)Cell Signaling Technology#9491, RRID:AB_2075144Rabbit Anti-β-Actin (13E5) HRP conjugatedCell Signaling Technology#5125, RRID:AB_1903890Goat Anti-Rabbit IgG HRP linked (secondary antibody)Cell Signaling Technology#7074 S, RRID:AB_2099233Horse Anti-Mouse IgG HRP linked (secondary antibody)Cell Signaling Technology#7076 S, RRID:AB_330924Rabbit Anti-CD4Abcam#ab133616, RRID:AB_2750883Rabbit Anti-Mouse/Human Ki-67Abcam#ab15580, RRID:AB_443209Normal Mouse IgGSanta Cruz BiotechnologyCat#sc-2025; RRID: AB_737182Mouse Anti-MALT1Santa Cruz BiotechnologyCat#sc-46677; RRID: AB_627909Biological samplesPrimary ATL patient samples (peripheral blood and lymph node)This studyEthics approval G-0010, G-1116, 2015-146Chemicals, peptides, and recombinant proteinsCRD-1441551This studyN/ALenalidomideFujifilm#120-06731Ac-LRSR-AFCSM Biochemicals LLC#SMAFC013Recombinant human IL-2Kyowa Pharmaceutical IndustryN/ARPMI 1640 MediumThermoFisher Scientific#11875500BTPenicillin-Streptomycin (100 U/mL Penicillin, 100 μg/mL Streptomycin)Fujifilm WakoCat#168-23191; JAN4987481473331Hank’s Balanced Salt SolutionThermoFisher Scientific#14170112BD Matrigel™ MatrixBD Biosciences#3562310.5% Methylcellulose (vehicle for in vivo dosing)N/AN/ACritical commercial assaysCellTiter-Glo® 2.0 Cell Viability AssayPromega#G9242SureSelect Custom KitAgilent TechnologiesN/AQuantiChrom™ Lactate Dehydrogenase KitBioAssay Systems#D2DH-100Human CD25/IL-2Rα Quantikine ELISA KitR&D Systems#DR2A00Protease selectivity panelEurofins PanlabsN/ADeposited dataGene expression (RNA-seq) from ATL cell linesThis studyDDBJ: PRJDB42075Gene expression (RNA-seq) from ATL PDX modelsThis studyJGA: JGAS000921Crystal structure of CRD-1441551This studyCCDC: 2561470Experimental models: Cell linesLM-Y1Dr. Hasegawa, Nagasaki UniversityCVCL_VN50LM-Y2Dr. Hasegawa, Nagasaki UniversityCVCL_VN51S1TDr. Ishitsuka, Kagoshima UniversityCVCL_1687OCI-Ly3ATCC#CRL-2631HEK293TATCC#CRL-3216Experimental models: Organisms/strainsMouse: NOD/Shi-scid, IL-2Rγnull (NOG)Central Institute for Experimental AnimalsN/AATL cell line xenograft (PDX)This studyN/AATL patient-derived xenograft (PDX)This studyN/ARecombinant DNAHis-LZ–MALT1 expression constructThis studyN/ABCL10 expression constructThis studyN/ACARD11 expression constructThis studyN/AMALT1A expression constructThis studyN/AMALT1B expression constructThis studyN/ANF-κB reporter (firefly luciferase) plasmidN/AN/ATK reporter (Renilla luciferase) plasmidN/AN/ASoftware and algorithmsGraphPad Prism 6GraphPad Softwarehttps://www.graphpad.com/API-5000 LC/MS/MSAB SciexN/AR version 4.0.3R Core Teamwww.r-project.orgGSVA R packageBioconductorhttps://bioconductor.org/packages/GSVA/fgsea R packageBioconductorhttps://bioconductor.org/packages/fgsea/Genomon pipelineGitHubhttps://github.com/Genomon-Project/Integrative Genomics ViewerBroad Institutehttps://software.broadinstitute.org/software/igv/; RRID:SCR_011793OtherBioruptorCosmo Bio Co., Ltd.Cat#UCW-310 Experimental model and study participant details Human samples This study was conducted following the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the Faculty of Medicine, University of Miyazaki, and participating institutions (G-0010, G-1116, and 2015-146). Written informed consent was obtained from all patients for the use of their clinical samples in genetic analyses and the generation of PDX models. Cell lines ATL cell lines were previously established45,46,47 by collaborators and are listed in the key resources table. Cells were cultured in RPMI medium supplemented with penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37°C in a humidified atmosphere containing 5% CO2. LM-Y1 and LM-Y2 cells were maintained in the presence of recombinant human IL-2 (50 U/mL). Short tandem repeat (STR)-based cell line authentication was not performed as part of this study. All experiments were performed with mycoplasma–free cells. Mice NOG mice were purchased from the Central Institute for Experimental Animals (Kanagawa, Japan). All animal experiments were approved by the University of Miyazaki Ethics Committee and participating institutions (approval no. 2017-520) and conducted in accordance with institutional guidelines. Method details Development of CRD-1441551 CRD-1441551 was generated by chemically optimizing seed compounds. The method for synthesizing CRD-1441551 is described in Table S1. MALT1 enzymatic assay A recombinant human LZ-MALT1 fusion protein, consisting of an N-terminal hexahistidine tag, a leucine zipper domain derived from Saccharomyces cerevisiae GCN4 (amino acids 251–281), a linker peptide (GSGSGSGS), and human MALT1 (amino acids 340–789), was expressed in Escherichia coli BL21(DE3). The protein was purified by Ni-NTA affinity chromatography followed by gel filtration chromatography. Purified recombinant protein was incubated with CRD-1441551 at the indicated concentrations for 60 min at room temperature, followed by incubation with Ac-LRSR-AFC as a fluorogenic substrate. Fluorescence was measured after an additional 60-min of incubation. Each concentration was assayed in tetraplicates. IC50 values were calculated using GraphPad Prism 6 based on percent inhibition. Protease selectivity assay Three micromolar CRD-1441551 was subjected to protease assay performed by Eurofins Panlabs, Inc. to determine the inhibition ratio (%). AS-MS direct binding and dissociation assays For the binding assay, AS-MS analysis was performed using recombinant His-LZ-MALT1 incubated with CRD-1441551 for 1 h at room temperature. Excess amounts of competitor compounds were added to the mixture of MALT1 and test compounds to estimate nonspecific binding. For the dissociation assay, MALT1 was incubated with CRD-1441551 at a concentration equivalent to the KD value of His-LZ-MALT1 for 1 h. After incubation, excess amounts of competitor compounds were added to initiate dissociation of the test compounds. In both direct binding and dissociation assays, compounds were separated on a reversed-phase column (#C18, Imtakt, Kyoto, Japan). Liberated compounds were quantified by liquid chromatography–mass spectrometry on an API-5000 LC/MS/MS system equipped with an electrospray ionization interface. The KD was calculated with GraphPad Prism 6 using a nonlinear iterative curve-fitting computer program, and the dissociation binding data were analyzed by fitting with the one-phase exponential decay model: Y = Span∗exp(-koff x) + Plateau. The dissociation half-life (t1/2) was determined using the following equation: t1/2 = ln(2)/koff. Targeted capture sequencing Targeted capture was performed using a SureSelect Custom Kit (Agilent Technologies, Santa Clara, CA, USA) as previously described,48 to analyze 39 driver genes in ATL (Table S2). Library preparation and sequencing were performed on the Illumina platform. Somatic mutations were identified using the Genomon pipeline (version 2.5.0 or 2.6.2; https://github.com/Genomon-Project/), and filtered by removing: (i) synonymous single nucleotide variants (SNVs); (ii) known polymorphisms listed in SNP databases unless previously reported as cancer mutations; (iii) variants supported only by unidirectional reads; (iv) variants within repetitive genomic regions; and (v) variants with <4 supporting reads in tumor samples. For ATL cell lines, variants with allele frequency <0.05 were additionally excluded. For primary clinical specimens and PDX models, variants with allele frequency <0.1 were excluded, along with missense SNVs with allele frequency of 0.4–0.6 or 0.9–1.0 unless identical mutations were found in other ATL cases or in the COSMIC database (version 70, ≥10 occurrences). For PDX model analyses, potential false-positive mutations arising from human–mouse genome cross-mapping were removed using matched normal mouse genomic DNA sequencing data. All final variants were confirmed by visual inspection using the Integrative Genomics Viewer (IGV; Broad Institute). CARD11 hotspot deletions involving exons 14–17 were reviewed manually in ATL cell lines. Generation of the cleaved BCL10 antibody Keyhole limpet hemocyanin–conjugated peptide of the carboxy-terminal of the human BCL10 protein (residual sequence 221–228 of carboxy-terminal human cleaved BCL10, MFLPLRSR) was synthesized as an antigen. The antigen was injected into rabbits to produce polyclonal antibodies. Western blotting analysis Cells were lysed by mixing with Buffer A (62.5 mM Tris-HCl (pH 7.5), 10% glycerol), and then adding an equal volume of Buffer B (2% sodium dodecyl sulfate (SDS), 62.5 mM Tris-HCl (pH 7.5), 10% glycerol). The lysates were processed using a previously established method.49 Antibodies used in this study are listed in Table S3. Immunoprecipitation Cell pellets were suspended in 200 μL of lysis buffer (0.2% NP-40 in PBS) and then subjected to sonication by Bioruptor (#UCW-310, Cosmo Bio Co., Ltd., Tokyo, Japan). Sonicated samples were cleared by centrifugation, and supernatants were collected. Two micrograms of each antibody, normal mouse IgG and MALT1 (#sc-2025 and #sc-46677, respectively), were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). These were added to separate lysate samples and incubated overnight at 4°C with rotation. After the antibody-beads reaction, the beads were washed, and the protein on the beads was eluted. In vitro proliferation assay of ATL cell lines ATL cell lines were cultured in RPMI medium supplemented with 100 U/mL penicillin/streptomycin in a humidified atmosphere of 5% CO2 at 37°C. LM-Y1 and LM-Y2 cells were cultured with human IL-2 (50 U/mL). Cells were suspended in 90 μL of appropriate media and seeded in a 96-well plate. Then, 10 μL of medium containing CRD-1441551 was added to each well to obtain final CRD-1441551 concentrations of 1, 3, 10, 30, 100, 300, 1000, 3000, and 10000 nmol/L (n = 3 for technical replicates). After adding either the medium with or without CRD-1441551, cells were cultured for 6 days. The viabilities of cell lines were measured before the initiation of incubation (Day 0) and 6 days after the initiation of incubation (Day 6) using the CellTiter-Glo 2.0 Cell Viability Assay (Promega Corporation, Madison, WI, USA). The IC50 and 50% growth inhibition (GI 50) values were calculated using GraphPad Prism 6 from the percentage of the control group. In vivo efficacy experiment in ATL cell lines Six-week-old female NOG mice were inoculated subcutaneously in the flank with a suspension of 1 × 107 S1T cells (0.1 mL in a 1:1 mixture of Hank’s Balanced Salt Solution (#14170112, Thermo Fisher Scientific Inc.) and BD Matrigel Matrix (#356231, BD Biosciences, Franklin Lakes, NJ, USA). Tumor growth was monitored with vernier calipers, and tumor volume was calculated using the formula (0.5 × [length × width2]). When the average tumor volume reached 200–300 mm3, the animals were randomized into four treatment groups (n = 6 per group) based on tumor volume and body weight on Day 0 (16 days after inoculation) to minimize intergroup differences at baseline. Mice were then dosed for 14 days with vehicle (0.5% methylcellulose), CRD-1441551 at 60 or 100 mg/kg (orally, twice daily), or lenalidomide at 30 mg/kg (orally, once daily). The tumor volume and body weight were measured twice per week until Day 15 after randomization. Generation of ATL PDX models and in vivo efficacy study To generate the ATL PDX model, ATL cells isolated from 20 patients were injected intravenously into NOG mice, each of which subsequently developed an intraperitoneal mass and hepatic infiltration 3–4 weeks after intravenous injection. To determine if successively transplanted ATL cells would settle in the recipient mice, 1 × 107 cells from these masses were subcutaneously transplanted into healthy NOG mice. For the in vivo efficacy study of CRD-1441551, mice were subcutaneously injected with 1 × 107 ATL PDX cells. Mice were randomly divided into two groups (five mice each) and treated orally with 60 mg/kg CRD-1441551 or vehicle twice daily for 21 days. Mice were sacrificed after oral administration or when the tumor size reached 2500 mm3. Pathological and immunohistochemical examinations Tissue samples from recipient mice were fixed in formalin, paraffin-embedded, and sectioned. Slides were stained with hematoxylin and eosin or human anti-CD4 primary antibody (1:500, #ab133616, Abcam, Waltham, MA, USA) and anti-Ki-67 primary antibody (1:100, #ab15580, Abcam) and subjected to detection and visualizationLDH and sIL-2R measurements. Blood samples were collected from ATL PDX–transplanted mice treated orally with vehicle or CRD-1441551 for 3 weeks. LDH levels in the collected blood were measured with the QuantiChrom TM Lactate Dehydrogenase Kit (#D2DH-100, BioAssay Systems, Hayward, CA, USA), whereas human sIL-2R levels were measured with the Human CD25/IL-2R alpha Quantikine ELISA Kit (#DR2A00, R&D Systems, Minneapolis, MN, USA). RNA-seq and signaling pathway analysis ATL cell lines were treated with vehicle or CRD-1441551 for 24 h. NOG mice engrafted with ATL PDX models received vehicle or CRD-1441551 for 21 days. Total RNA was extracted, and gene expression levels were quantified as counts per million and log2-transformed. For each model, biological replicates were averaged (n = 2 per condition for cell lines; n = 3 per condition for PDX models) prior to downstream analyses. To assess CBM–NF-κB pathway activity, we defined a MALT1-dependent NF-κB target gene set comprising NFKBIZ, NFKBID, and ZC3H12A (post-transcriptionally regulated by MALT1 protease activity)34; IRF4 and MYC (direct NF-κB targets forming a feedforward loop in ATL cells)35; and ICOS and CTLA4 (induced downstream of CARD11 gain-of-function mutations).36 Hallmark gene sets for mTORC1, IL6–JAK–STAT3, and Hedgehog signaling were obtained from MSigDB. Baseline pathway activity was evaluated using ssGSEA (GSVA R package) under vehicle-treated conditions, with enrichment scores Z-scored within each panel. Treatment-induced changes were assessed using GSEA (fgsea R package), with genes ranked by fold change (treated vs. untreated). Normalized enrichment scores (NES) and nominal p-values were calculated using 1,000 permutations. Quantification and statistical analysis Statistical analysis Data are expressed as mean ± standard deviation, and differences were considered statistically significant at p < 0.05, as determined by the paired Student’s t test. Tumor growth in the PDX experiment was assessed using two-way ANOVA test.